GTHX - Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Benzinga
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world evidence indicating that trilaciclib administered prior to platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) lowers the rate of hospitalization and cytopenia events and may improve survival. In addition, multiple real-world analyses indicate the consistent impact of chemotherapy-induced myelosuppressive events, including severe neutropenia, thrombocytopenia, and anemia, on patients with ES-SCLC being treated with platinum-based chemotherapy as well as the resulting impact on healthcare resource utilization. The posters are being presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA. A copy of the posters will be made available on the G1 Therapeutics website following the presentations here.
"The burden of chemotherapy-induced myelosuppression not only puts patients at risk for serious adverse events but can also stress the healthcare system," said Raj Malik, M.D., Chief Medical Officer at G1 Therapeutics. "Findings from these real-world analyses demonstrate the need to protect patients from the harmful side effects of chemotherapy so that they can continue their treatment. Trilaciclib offers the potential to transform the treatment experience, and these new data underscore the results we've seen across multiple analyses showing the positive impact of proactive treatment with trilaciclib."
The poster presentations include:
Myelosuppression and Healthcare Utilization Among Patients with Chemotherapy-Treated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) with and without Trilaciclib from Community Oncology Practices (Gajra, A. et al.)
This observational study compared cytopenia-related outcomes and HRU between patients with ES-SCLC who received trilaciclib prior to chemotherapy vs. those who did not in a real-world setting. Using the EMOL Health's database, which includes >7 million patients from >500 U.S. community oncology practices, structured electronic medical records (EMRs) from January 2020 to April 2023 were examined for this study, supplemented by chart review. Descriptive analyses were performed for patient baseline characteristics and outcomes between the two matched cohorts. Adjusted analyses were conducted to evaluate grade ?3 myelosuppression in ?1, ?2, and all three lineages, as well as all-cause hospitalization.
Results of this retrospective study suggest that patients receiving trilaciclib prior to chemotherapy (n=77) in cycles 1-4 had lower rates of grade ?3 myelosuppressive HAEs and cytopenia-related HRU compared to the matched comparison cohort (n=77) not treated with trilaciclib:
- 11.2% of trilaciclib-treated patients had grade ?3 HAEs in ?1 lineage compared to 30.7% of patients in the comparison cohort.
- 1.2% of trilaciclib-treated patients had grade ?3 HAEs in ?2 lineages compared to 13.5% of patients in the comparison cohort.
- 0.4% of trilaciclib-treated patients had grade ?3 HAEs in 3 lineages compared to 4.9% of patients in the comparison cohort.
G-CSF administered any time during the cycle was reduced by 60.7% in patients receiving trilaciclib compared to those not receiving trilaciclib in the comparison cohort (25.6% vs. 65.2%). Similarly, RBC transfusions and erythropoiesis-stimulating agent (ESA) use were reduced by 84.4% (1.7% vs. 10.9%) and 42.2% (3.7% vs. 6.4%), respectively, in patients receiving trilaciclib compared to those that did not.
After adjusting for age, sex, index line of therapy, and number of chemotherapy cycles receiving trilaciclib, the odds of developing an event of grade ?3 myelosuppression in ?1, ?2, and 3 lineages were reduced by 70%, 90%, and 96%, respectively, with trilaciclib ...